title: Multiple-dose vaginal misoprostol and single-dose misoprostol plus oxytocin for termination of second-trimester pregnancy.
abstract: OBJECTIVE
  To compare 2 different methods-multiple doses of misoprostol and a combination of misoprostol and oxytocin-for termination of pregnancy in the second trimester.
  
  
  METHODS
  Between 2006 and 2008, 120 women undergoing termination of second-trimester pregnancy in 2 hospitals in Kermanshah, Iran, were enrolled in a randomized trial comparing 2 treatments. In each treatment group, an initial vaginal dose of 600 μg of misoprostol was placed in the posterior fornix. After 6 hours, an intravenous infusion of concentrated oxytocin was given to women in group A, and 400 μg of vaginal misoprostol was given every 6 hours to women group B, up to a maximum of 4 doses. The outcomes were compared via χ(2) and independent t tests.
  
  
  RESULTS
  Within 30 hours, 96.7% of women in group A and 96.7% of women in group B delivered successfully. The average duration between induction and delivery time was 12.3±6.0 hours in group A and 12.1±6.0 hours in group B (P>0.05).
  
  
  CONCLUSIONS
  The use of misoprostol with oxytocin, and multiple doses of misoprostol gave similar results for termination of pregnancy in the second trimester.
authors.affiliation: High Risk Pregnancy Research Center, Department of Obstetrics and Gynecology, Imam Reza Hospital, Kermanshah University of Medical Science, Kermanshah, Iran. mzangene.59710@yahoo.com
authors.forename: Maryam
authors.initials: M
authors.lastname: Zangeneh
authors.forename: Shohreh
authors.initials: S
authors.lastname: Malek-Khosravi
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Veisi
authors.forename: Negin
authors.initials: N
authors.lastname: Rezavand
authors.forename: Mansour
authors.initials: M
authors.lastname: Rezaee
authors.forename: Mozhgan
authors.initials: M
authors.lastname: Rajatee
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000009:adverse effects / Q000379:methods*; D000282:Administration, Intravaginal; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007492:Iran; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D010121:Oxytocin / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D016037:Single-Blind Method; D013997:Time Factors; D055815:Young Adult
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin